ENZ Enzo Biochem Dashboard

Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.

Company profile

Ticker

ENZ

Exchange

NYSE

Website

www.enzo.com/

CEO

Elazar Rabbani

Incorporated

New York

Location

New York

Fiscal year end

Jul 31

Sector

Professional, Scientific, and Technical Services > Testing Laboratories

Industry (SIC)

Services - Medical Laboratories

Quest Diagnostics • Laboratory Corp. Of America • Radnet • Burning Rock Biotech • Guardant Health • Genomic Health • Invitae • Natera • Progenity • Centogene ...

SEC CIK

0000316253

Corporate docs

Articles of Incorporation & Bylaws

IRS number

132866202

ENZ stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Enzo Biochem Announces FDA Has Cleared Its AMPICOLLECT Sample Collection Kit

21 Apr 21

Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, today announced that the Food and Drug Administration ("FDA") has cleared its

180 Degree Capital Sends Letter To Board, Shareholders Of Enzo Biochem

22 Mar 21

To The Independent Directors of Enzo, Dov Perlysky Rebecca Fischer Dr. Ian Walters Dr. Mary Tagliaferri This is a highly bothersome and rather disappointing second public letter that I feel we must write to you, the

66 Biggest Movers From Yesterday

17 Mar 21

Gainers SunLink Health Systems, Inc. (NYSE: SSY) shares climbed 151.3% to close at $4.85 on Tuesday as the company reported $2 million expansion, capital and operating improvements at Trace Regional Hospital.

12 Health Care Stocks Moving In Tuesday's Intraday Session

16 Mar 21

Stocks That Hit 52-Week Highs On Tuesday

16 Mar 21

Press releases

Pro users get this 30m faster

ENZO BIOCHEM TO PRESENT AT THE KEYBANC CAPITAL MARKETS' LIFE SCIENCES & MEDTECH INVESTOR FORUM

17 Mar 21

NEW YORK, NY, March 17, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Markets' Life

Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates

15 Mar 21

Total second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemicSecond quarter clinical laboratory revenue of $24.0 million increased 92% on

Enzo Biochem, Inc. to Host Earnings Call

15 Mar 21

NEW YORK, NY / ACCESSWIRE / March 15, 2021 / Enzo Biochem, Inc. (NYSE:ENZ) will be discussing their earnings results in their 2021 Second Quarter Earnings call to be held on March 15, 2021 at 4:30 PM Eastern Time.To

Enzo Biochem to Report Second Quarter 2021 Financial Results on Monday, March 15

1 Mar 21

Calendar

16 Mar 21

22 Apr 21

31 Jul 21

Financial summary

Financial statements Chart ENZ financial data

Quarter (USD)	Jan 21	Oct 20	Jul 20	Apr 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jul 20	Jul 19	Jul 18	Jul 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	45.29M	45.29M	45.29M	45.29M	45.29M	45.29M
Cash burn (monthly)	459.33K	580.5K	(positive/no burn)	946.33K	273.33K	934.67K
Cash used (since last report)	1.26M	1.59M	n/a	2.6M	749.97K	2.56M
Cash remaining	44.03M	43.69M	n/a	42.69M	44.54M	42.72M
Runway (months of cash)	95.8	75.3	n/a	45.1	162.9	45.7

Beta Read what these cash burn values mean

Recent insider trades

ENZ insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Mar 21	Harbert Management	Common Stock	Sell	Dispose S	Yes	No	4.539	100,000	453.9K	5,175,913
16 Mar 21	Harbert Management	Common Stock	Sell	Dispose S	Yes	No	4.7	200,000	940K	5,275,913
15 Mar 21	Harbert Management	Common Stock	Sell	Dispose S	Yes	No	5	44,768	223.84K	5,475,913
15 Mar 21	Harbert Management	Common Stock, $0.01 par value ("Common Stock")	Sell	Dispose S	Yes	No	4.75	100,000	475K	5,520,681
11 Jan 21	Ian B. Walters	Stock Option (to acquire Common Stock) Common Stock	Grant	Aquire A	No	No	2.63	77,101	202.78K	77,101
11 Jan 21	David Bench	Stock Option (to acquire Common Stock) Common Stock	Grant	Aquire A	No	No	2.63	55,400	145.7K	110,800
11 Jan 21	Elazar Rabbani	Common Stock, par value $0.01 per share	Grant	Aquire A	No	No	0	190,114	0	2,262,208
11 Jan 21	Perlysky Dov	Stock Option (to acquire Common Stock) Common Stock	Grant	Aquire A	No	No	2.63	77,101	202.78K	335,780

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

ENZ institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

72.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	83	83	–
Opened positions	7	9	-22.2%
Closed positions	7	10	-30.0%
Increased positions	24	23	+4.3%
Reduced positions	24	27	-11.1%

13F shares	Current	Prev Q	Change
Total value	108.89M	81.84M	+33.1%
Total shares	34.9M	28.92M	+20.7%
Total puts	163K	34.2K	+376.6%
Total calls	53.5K	37.8K	+41.5%
Total put/call ratio	3.0	0.9	+236.7%

Largest owners	Shares	Value	Change
Harbert Fund Advisors	5.62M	$14.16M	0.0%
Harbert Discovery Fund	5.62M	$14.67M	NEW
BLK Blackrock	3.76M	$9.46M	+4.1%
Renaissance Technologies	3.56M	$8.96M	-0.9%
Roumell Asset Management	2.77M	$6.98M	+17.6%
Evermore Global Advisors	2.61M	$6.57M	-11.7%
Vanguard	2.4M	$6.04M	+0.7%
Dimensional Fund Advisors	1.7M	$4.29M	-11.4%
Ariel Investments	871.11K	$2.2M	+4.8%
STT State Street	847.55K	$2.14M	+4.7%

Largest transactions	Shares	Bought/sold	Change
Harbert Discovery Fund	5.62M	+5.62M	NEW
Roumell Asset Management	2.77M	+415K	+17.6%
Evermore Global Advisors	2.61M	-344.6K	-11.7%
Dimensional Fund Advisors	1.7M	-219.58K	-11.4%
VIEX Capital Advisors	155.48K	+155.48K	NEW
BLK Blackrock	3.76M	+146.25K	+4.1%
Russell Investments	0	-125.29K	EXIT
Group One Trading	140.13K	+119.9K	+592.8%
JPM JPMorgan Chase & Co.	132.22K	+111.23K	+530.0%
Simplex Trading	122.04K	+103.77K	+567.9%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ACLA, appointing, assigned, bank, calendar, fewer, impose, intermediary, larger, lending, median, methodology, nineteen, opposition, paper, qualify, reform, senior, stringent

Removed: awarded, comparative, geography, substantially, timing, updated, variance, vested

From filing 10-Q 2021 Q2